Zimbabwe has declined a substantial American healthcare agreement valued at $367m (£272m) over five years over Washington's demand for sensitive data.
This rejection came to light after a official document dated December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the deal was "skewed".
A government spokesman has since clarified that the US was requesting biological samples for scientific study and profit but was unwilling to share the resulting advantages from any future medical innovations.
"We must now begin the difficult and regrettable task of ending our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had donated more than $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for more talks to find a deal suitable to all parties so the country's critical HIV programme can proceed.
Wider Background
This rejection follows a comparable case in Kenya, where a court suspended a similar deal with the US after legal challenges were filed about the safety of Kenyans' medical information.
Since returning to the presidency last year, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
The agency had managed aid for the US government, but Trump stated its spending was "wasteful" and his administration was pursuing government-to-government agreements to enhance openness and responsibility.
According to statements, Sixteen African countries have so far agreed to these new health pacts, representing over $18.3bn in new funding.
Details of the Rejected Deal
The funds for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation might have yielded immense benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving antiretroviral therapy via US-supported programmes," Tremont added.
However, government spokesperson Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to provide its biological resources and data indefinitely, without any corresponding promise of access to any medical innovations – such as new medicines or tests – that might be developed from that provided information," Mangwana explained.
"Effectively, our nation would provide the basic resources for medical research without any certainty that the final treatments would be available to our people should a new health crisis emerge."
Sovereignty and Global Health
He also pointed out that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were disrupting systems previously set up through the global health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing framework created to deal with potential global health emergencies.
"This system is designed to ensure that when a country contributes its data, the benefits – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to develop them."
The government's concerns regarding the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We are open to continued dialogue with our US partners on how subsequent co-operation might be structured in a way that honours the independence and interests of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the official position, but urged that talks need to persist since much of the country's HIV programmes were funded by foreign aid.
"Where technical issues exist, such as those relating to data governance or implementation frameworks, these can often be addressed through detailed discussion and negotiated safeguards," the group added.
The halted deal highlights the complex tensions between accepting crucial foreign assistance and protecting local interests in an increasingly data-driven world.